The effect of an adenosine (Ado) A 2 receptor agonist, N 6 -[2-(3,5-dimethoxyphenyl)-2-(2- reversed the effect of DPMA on AdoA 1 R mediated negative inotropic actions while the adoA 2B R inhibitor (alloxazine, 3 µM) had no effect on DPMA activity.
INTRODUCTION
Endogenous adenosine affects many aspects of cardiac function due to activation of the adenosine A 1 , A 2 and A 3 receptor (AdoR) subtypes. The adenosine receptor subtypes are found on different regions of the heart. AdoA 1 Rs are located predominantly in cardiomyocytes where they exert direct inhibitory effects on chronotropy, dromotropy and inotropy (1, 2) . The physiological effects of adenosine mediated by AdoA 1 R act to reduce the oxygen demand of the heart, thereby reducing myocardial ischaemia-reperfusion injury (3) . The AdoR 2A Rs and AdoA 2B Rs are mainly located on the endothelium and vascular smooth muscle with a low density of adoA 2A R found on ventricular myocytes (1,
2, 4, 5).
In rat ventricular myocytes, AdoA 1 R mediated negative inotropic actions are associated with activation of inward rectifying K + current I K(Ado) and inhibiting isoproterenol stimulated L-type Ca 2+ current (6) . AdoA 2 Rs increase levels of intracellular cAMP via a pertussis-toxin insensitive Gs protein (7, 8) .
Interestingly, interactions between adenosine receptors in the cardiovascular system have been reported. For example, deletion of AdoA 3 Rs augments AdoA 2A R induced vasodilation in murine hearts (9) . Other studies have demonstrated that AdoA 1 R-mediated electrophysiological effects may be modulated by myocardial AdoA 2 R (10, 11).
In the chick ventricular heart cells both subtypes of AdoA 2 R's have been demonstrated to have greatly different affinities for NECA, coexist and are coupled to the same positive inotropic cardiac responses (12) . Furthermore, there is recent evidence of AdoA 2 Rmediated modulation of the "indirect" anti-adrenergic effects of AdoA 1 Rs (13). In rat cardiac tissues both AdoA 2A R and AdoA 2B R are expressed (14, 15) . Little work has been published on the role of AdoA 2B R in modifying the actions of AdoA 1 R in the heart.
The aims of this study were to examine the impact of AdoA 2 R activation on AdoA 1 Rmediated inotropic responses, to determine the AdoA 2 R subtype involved in modifying AdoA 1 R induced cardiac actions, and to establish whether cAMP is a second messenger system involved.
METHODS

Animals
Male Wistar rats (250-350 g) were obtained from the central animal house located at the University of Queensland. They were housed in a room maintained at an ambient temperature of 23±2 o C with a twelve hour light-dark cycle. The rats had free access to food and water at all times. The conduct of all experiments conformed to the guidelines for animal experimentation as determined by the National Health and Medical Research
Council of Australia and approved by the Griffith University Animal Experimentation Ethics Committee.
Isolated perfused rat hearts
Rats were anaesthetised with pentobarbitone (60 mg/kg, intraperitoneally). Rat hearts were perfused in the non-recirculating Langendorff mode based on a method described by Harrison et al., (16) . Briefly, hearts were rapidly excised and immersed into ice-cold 
Data analysis.
Unless stated otherwise, all values shown are means ± S.E.M. All data were analysed using a repeated measures ANOVA followed by the Newman-Keuls post hoc test for individual comparisons when significant effects was detected. Concentration-response curves to the DPMA and R-PIA were analysed by nonlinear regression using the program GraphPad Prism, EC 50 and confidence interval (CI) values were derived from these curves. Differences were considered significant at P<0.05.
Materials.
R-PIA, DPMA, CSC, alloxazine, DPCPX and MDL-12330A were all purchased from Sigma Chemicals (Castle Hill, Australia). DPMA and CSC was added directly to perfusing fluid from 100 µM stock (in ~1% DMSO) and diluted to achieve a 10 nM final concentration. DPCPX (0.5 mM) stock was dissolved in DMSO then diluted 1 in 10 000
to give a final concentration of 50 nM. Dilutions of R-PIA were prepared in buffer from a 0.5 mM stock. Alloxazine stock (10 mM) was dissolved in distilled water with 50µl NaOH (10 M) and added to the perfusing solution prior to use. MDL 12330A (1 mM) stock was made up in distilled water and stored in frozen aliquots (-80 0 C) until required.
Results
The effect of drug treatments on basal functional parameters in isolated perfused
hearts.
Functional variables under basal conditions are presented in table 1. LVDP and dP/dt min
were comparable in all groups tested. CPP was reduced by 41% in DMPA treated hearts compared to control hearts (P<0.05). dP/dt max was reduced in DPCPX (50 nM) and alloxazine (3 µM) treated tissues when compared to untreated controls (P<0.05).
However, in CSC (1 µM) treated tissues dP/dt max values were higher than control data (P<0.05). The combination of DMPA and alloxazine or CSC returned dP/dt max values to control levels.
Effect of adenosine A 2 receptor activation on adenosine A 1 receptor-mediated decreases in heart inotropic responses.
R-PIA induced concentration-dependent reductions in triple product which were inhibited by DPCPX (50 nM, see Table 2 ). The addition of the AdoA 2 R agonist DPMA (1 nM) did not alter contractility in paced hearts, as measured by the triple product (P<0.05). DPMA 
Effect of inhibitors on adenosine A 1 receptor-mediated decreases in triple product.
Addition of CSC (1 µM) and DPMA (1 nM) reversed effects of DPMA on R-PIA mediated reductions in contractility (see Fig 3A, P<0.05). The attenuation of the R-PIA response by DPMA was not altered by co-treatment with alloxazine (3 µM) (P>0.05, Fig   3A) . These data indicate AdoA 2A R's are responsible for reducing AdoA 1 R mediated decreases in inotropic state in rat heart.
The addition of the adenylyl cyclase inhibitor MDL12330A (100 nM) reversed the effect DPMA on the negative inotropic response to R-PIA (P<0.05, see table 1 and Fig. 3B ).
Use of CSC, alloxazine or MDL12330A alone did not alter R-PIA concentrationresponse curves with pEC 50 values or maximal decreases in triple product remaining unchanged (see Table 2 ).
This data implies that AdoA 2 Rs reverse AdoA 1 R mediated cardiac responses through stimulation of adenylyl cyclase. CGS21680 also acts a partial agonist (19) and will alter its binding behaviour in low receptor populations as observed in heart tissue.
Another study has shown that the AdoA 2 R modulates the indirect anti-adrenergic effects of AdoA 1 R on contractile function (13) . In rat ventricular myocytes, AdoA 1 R mediated inhibition of cardiac contractility is associated with activation of inward rectifying K + current I K(Ado) and inhibiting isoproterenol stimulated L-type Ca 2+ current (7) . The actions of AdoA 1 R are reported to be due to inhibition of adenylyl cyclase (20) , or activation of other mediators including nitric oxide and cGMP (21) or phosphoinositide-PKC-ε (22, 23) .
In our study, DPMA significantly attenuated the negative inotropic effects of R-PIA, Also, in the present study, the adenylyl cyclase inhibitor MDL-12330A (27) was employed to determine whether AdoA 2A R-mediated attenuation of the negative inotropic effects of AdoA 1 R activation was due to an increase in cAMP levels. In support of this possibility, MDL12330A, reversal of the effect of DPMA on AdoA 1 R mediated negative inotropic actions. MDL12330A however, did not completely reverse the effects of DPMA, indicating a possible role for other second messengers to be involved.
In conclusion, the results of the present study demonstrate that AdoA 2 R significantly attenuates AdoA 1 R mediated decreases in inotropic state. The adenosine receptor subtype involved in this response is the AdoA 2A R subtype, and its mechanism of action may involve stimulating adenylyl cyclase activity. This study has revealed a more complex interplay between AdoRs in the control of cardiac physiological function than was previously appreciated. 
